2025
MAP Kinase Phosphatase-5 Deficiency Improves Endurance Exercise Capacity
Perales J, Lawan A, Bajpeyi S, Han S, Bennett A, Min K. MAP Kinase Phosphatase-5 Deficiency Improves Endurance Exercise Capacity. Cells 2025, 14: 410. PMID: 40136658, PMCID: PMC11941502, DOI: 10.3390/cells14060410.Peer-Reviewed Original ResearchConceptsResponse to aerobic exerciseEndurance exercise capacityAerobic exerciseExercise capacityProgressive exercise stress testExercise training programEnhance endurance performanceCardiac adaptationPhysiological cardiac adaptationExercise stress testExercise habituationEndurance performanceRunning distanceCardiovascular healthTreadmill exerciseTraining programExerciseImproving cardiovascular functionSedentary miceTreadmillCardiac muscleEnduranceMitogen-activated protein kinaseMuscleStress testCardiac Rehabilitation Among Veterans
Varghese M, Wu W, Drwal K, Burg M, Kazi D, Gaffey A, Mattocks K, Brandt C, Bastian L, Gandhi P. Cardiac Rehabilitation Among Veterans. Journal Of Cardiopulmonary Rehabilitation And Prevention 2025, 45: 78-84. PMID: 40014636, DOI: 10.1097/hcr.0000000000000932.Peer-Reviewed Original ResearchConceptsLocal VA medical centersHome-based CRCardiac rehabilitationVA Medical CenterVeterans Affairs (VA) healthcare systemIn-personImpact of mental healthU.S. veteransIntegrated care networksSecondary prevention interventionsMedical CenterCardiac rehabilitation outcomesImprove exercise capacityRisk of cardiovascular diseaseAttend CRIncreased risk of cardiovascular diseaseRehabilitation outcomesCR utilizationCare networkMental healthPreventive interventionsRacial disparitiesDepressive symptomsHealthcare systemExercise capacityAficamten vs Metoprolol for Obstructive Hypertrophic Cardiomyopathy MAPLE-HCM Rationale, Study Design, and Baseline Characteristics
Garcia-Pavia P, Bilen O, Burroughs M, Costabel J, de Barros Correia E, Dybro A, Elliott P, Lakdawala N, Mann A, Nair A, Nassif M, Poulsen S, Reant P, Schulze P, Wang A, Berhane I, Heitner S, Jacoby D, Kupfer S, Malik F, Meng L, Sohn R, Wohltman A, Fifer M, Investigators M. Aficamten vs Metoprolol for Obstructive Hypertrophic Cardiomyopathy MAPLE-HCM Rationale, Study Design, and Baseline Characteristics. JACC Heart Failure 2025, 13: 346-357. PMID: 39909646, DOI: 10.1016/j.jchf.2024.11.011.Peer-Reviewed Original ResearchConceptsObstructive hypertrophic cardiomyopathyStandard-of-careCardiac myosin inhibitorStandard-of-care medicationsBaseline characteristicsSymptomatic obstructive hypertrophic cardiomyopathyNondihydropyridine calcium channel blockersBaseline characteristics of patientsStandard-of-care drugsSecond-line therapyFirst-line therapyCalcium channel blockersCharacteristics of patientsImprove exercise capacityMyosin inhibitorFirst-lineBeta-blockersHypertrophic cardiomyopathyExercise capacityAlleviate symptomsPatientsAficamtenMedicationTherapyStudy design
2024
Evaluating fatigue and excessive daytime sleepiness: a comparative analysis of prevalence and correlating factors in interstitial lung disease patients and healthy controls
Ouyang X, Shen Q, Zhou S, Zhou P, Song M, Guo T, Guo W, Zhang Y, Peng H. Evaluating fatigue and excessive daytime sleepiness: a comparative analysis of prevalence and correlating factors in interstitial lung disease patients and healthy controls. Annals Of Medicine 2024, 56: 2398729. PMID: 39624966, PMCID: PMC11616753, DOI: 10.1080/07853890.2024.2398729.Peer-Reviewed Original ResearchInterstitial lung disease patientsInterstitial lung diseaseDiminished exercise capacityExcessive daytime sleepinessHealthy volunteersExercise capacityDaytime sleepinessEpworth Sleepiness Scale scoreQuality of lifePulmonary diffusion functionSleepiness Scale scoreFactors associated with excessive daytime sleepinessSecond Xiangya HospitalLogistic regressionLung disease patientsMultivariate logistic regressionDecreased quality of lifeCentral South UniversityCross-sectional studyPrevalence of fatigueChest painConsecutive patientsClinical characteristicsNon-ED patientsLung diseaseThe metabolic and physiologic impairments underlying long COVID associated exercise intolerance
Leitner B, Joseph P, Quast A, Ramirez M, Heerdt P, Villalobos J, Singh I. The metabolic and physiologic impairments underlying long COVID associated exercise intolerance. Pulmonary Circulation 2024, 14: e70009. PMID: 39544193, PMCID: PMC11560803, DOI: 10.1002/pul2.70009.Peer-Reviewed Original ResearchPeak VO<sub>2</sub>Long COVID patientsCOVID patientsReduced peak VOSeverity of SARS-CoV-2 infectionSystemic oxygen extractionSARS-CoV-2 infectionLong COVIDArterial blood samplesQuantitative metabolomicsPeak VOVenous lactateCardiac outputImpaired mitochondrial ATP productionMild infectionExercise capacityPatientsMitochondrial ATP productionExercise intoleranceArteriovenous gradientBlood samplesOxygen extractionDependent mannerMetabolomicsPhysiological impairmentImpact of Aficamten on Disease and Symptom Burden in Obstructive Hypertrophic Cardiomyopathy Results From SEQUOIA-HCM
Maron M, Masri A, Nassif M, Barriales-Villa R, Abraham T, Arad M, Cardim N, Choudhury L, Claggett B, Coats C, Düngen H, Garcia-Pavia P, Hagège A, Januzzi J, Kulac I, Lee M, Lewis G, Ma C, Michels M, Oreziak A, Owens A, Spertus J, Solomon S, Tfelt-Hansen J, van Sinttruije M, Veselka J, Watkins H, Jacoby D, Heitner S, Kupfer S, Malik F, Meng L, Wohltman A, Olivotto I, Investigators S. Impact of Aficamten on Disease and Symptom Burden in Obstructive Hypertrophic Cardiomyopathy Results From SEQUOIA-HCM. Journal Of The American College Of Cardiology 2024, 84: 1821-1831. PMID: 39352339, DOI: 10.1016/j.jacc.2024.09.003.Peer-Reviewed Original ResearchObstructive hypertrophic cardiomyopathyN-terminal pro-B-type natriuretic peptidePro-B-type natriuretic peptideSeptal reduction therapyHypertrophic cardiomyopathyNatriuretic peptideReduction therapySymptomatic obstructive hypertrophic cardiomyopathyExercise capacityCardiac myosin inhibitorProportion of patientsTreatment of patientsHemodynamic responseAssociated with substantial improvementsOutflow gradientPlacebo groupAficamtenEnhanced exercise capacityClinical efficacyEfficacy measuresClinical impactPlaceboResponder analysisPatientsCardiomyopathyDiastolic Stress Echocardiography in Patients With Hypertrophy Cardiomyopathy: Association With Exercise Capacity
Fava A, Popovic Z, Alashi A, Thamilarasan M, Xu B, Desai M. Diastolic Stress Echocardiography in Patients With Hypertrophy Cardiomyopathy: Association With Exercise Capacity. The American Journal Of Cardiology 2024, 232: 34-40. PMID: 39307332, DOI: 10.1016/j.amjcard.2024.09.017.Peer-Reviewed Original ResearchTreadmill exercise echocardiographyHypertrophic cardiomyopathyCongestive heart failureDiastolic parametersExercise capacityStress echocardiographyAssociated with reduced exercise capacityPrecipitate congestive heart failureLeft ventricular (LVAsymptomatic/minimally symptomatic patientsDiastolic stress echocardiographyMultivariate logistic regression analysisSymptomatic HCM patientsEtiology of dyspneaHigher Body Mass IndexBody mass indexReduced exercise capacityExercise functional capacityLogistic regression analysisAssociated with <Incremental diagnostic utilityHigher LAViLVOT gradientE/e' ratioDiastolic dysfunctionEfficacy and Safety of Aficamten in Patients with Obstructive Hypertrophic Cardiomyopathy and Very High Left Ventricular Outflow Tract Gradients
Veselka J, Abraham T, Barriales-Villa R, Claggett B, Coats C, Hegde S, Januzzi J, Maron M, Masri A, Miao Z, Nassif M, Olivotto I, Jacoby D, Heitner S, Kupfer S, Malik F, Meng L, Wohltman A, Gimeno J. Efficacy and Safety of Aficamten in Patients with Obstructive Hypertrophic Cardiomyopathy and Very High Left Ventricular Outflow Tract Gradients. Journal Of Cardiac Failure 2024, 30: s9. DOI: 10.1016/j.cardfail.2024.08.014.Peer-Reviewed Original ResearchObstructive hypertrophic cardiomyopathyOutflow tract gradientSecondary endpointsHypertrophic cardiomyopathyCardiac biomarkersPhase 3 placebo-controlled trialsLeft ventricular outflow tract gradientGroup 2Group 1Symptomatic obstructive hypertrophic cardiomyopathyTreatment-emergent adverse eventsExercise capacityEmergent adverse eventsBaseline to weekEffective treatment optionInhibitor therapyNT-proBNPPrimary endpointEchocardiographic dataBetween-group differencesBaseline characteristicsAficamtenAdverse eventsTreatment optionsSymptom reliefAssociation between growth differentiation factor-15 and adverse outcomes among patients with heart failure: A systematic literature review
Javaheri A, Ozcan M, Moubarak L, Smoyer K, Rossulek M, Revkin J, Groarke J, Tarasenko L, Kosiborod M. Association between growth differentiation factor-15 and adverse outcomes among patients with heart failure: A systematic literature review. Heliyon 2024, 10: e35916. PMID: 39229539, PMCID: PMC11369438, DOI: 10.1016/j.heliyon.2024.e35916.Peer-Reviewed Original ResearchGDF-15 concentrationsGrowth differentiation factor 15Differentiation factor 15GDF-15Heart failureMultivariate analysisRenal functionComposite outcomeAdverse outcomesOptimal treatment regimensPredictors of mortalityCardiovascular-related mortalityCross-sectional studyPrognostic roleTreatment regimensClinical risk prediction modelsPoor outcomeRisk prediction modelExercise capacityEligibility criteriaPatientsPRISMA guidelinesMortalityNonfatal outcomesOutcomesPrevalence and prognostic importance of exercise limitation and physical inactivity in COPD
Vaes A, Burtin C, Casaburi R, Celli B, Evans R, Lareau S, Nici L, Rochester C, Troosters T. Prevalence and prognostic importance of exercise limitation and physical inactivity in COPD. Breathe 2024, 20: 230179. PMID: 38873237, PMCID: PMC11167648, DOI: 10.1183/20734735.0179-2023.Peer-Reviewed Original ResearchPhysical inactivityExercise limitationWalk testExercise performanceEndurance shuttle walk testExercise capacityMeasures of exercise performanceShuttle walk testAssess exercise capacityAssociated with mortalityExerciseDisease burdenInactivityPredictive of adverse outcomesAdverse outcomesCOPDAdditional resourcesNegative outcomesOutcomesTreadmillRespiratory impairmentEnduranceCliniciansPrevalenceBurdenDo pulmonary rehabilitation programmes improve outcomes in patients with COPD posthospital discharge for exacerbation: a systematic review and meta-analysis
Jenkins A, Burtin C, Camp P, Lindenauer P, Carlin B, Alison J, Rochester C, Holland A. Do pulmonary rehabilitation programmes improve outcomes in patients with COPD posthospital discharge for exacerbation: a systematic review and meta-analysis. Thorax 2024, 79: 438-447. PMID: 38350731, DOI: 10.1136/thorax-2023-220333.Peer-Reviewed Original ResearchHealth-related quality of lifeIntervention-related adverse eventsPulmonary rehabilitation programmeWeeks of hospital dischargeChronic obstructive pulmonary diseasePulmonary rehabilitationHealth-related qualityQuality of lifeExacerbation of chronic obstructive pulmonary diseaseRehabilitation programmeEfficacy of pulmonary rehabilitationExercise capacityPosthospital dischargeChronic obstructive pulmonary disease assessment testSystematic reviewHospital dischargeInpatient pulmonary rehabilitationCochrane Airways Review Group Specialised RegisterDimension-5 LevelImprove exercise capacityHospital re-admissionObstructive pulmonary diseaseGroup Specialised RegisterCochrane reviewAdverse events
2023
Differential cardiopulmonary haemodynamic phenotypes in PASC-related exercise intolerance
Kahn P, Joseph P, Heerdt P, Singh I. Differential cardiopulmonary haemodynamic phenotypes in PASC-related exercise intolerance. ERJ Open Research 2023, 10: 00714-2023. PMID: 38348243, PMCID: PMC10860209, DOI: 10.1183/23120541.00714-2023.Peer-Reviewed Original ResearchInvasive cardiopulmonary exercise testingRight heart catheterizationPASC patientsExertional intoleranceCardiac outputPulmonary artery wedge pressurePeak VO 2Supranormal cardiac outputPeak exercise capacityCardiopulmonary exercise testingMaximal voluntary ventilationPost-acute sequelaeBody mass indexSystemic oxygen extractionMild acute illnessSARS-CoV-2Exercise hemodynamicsHFpEF patientsHFpEF phenotypeHeart catheterizationWedge pressureAcute illnessExercise capacityExercise testingHemodynamic abnormalitiesLonger-Term Outcomes Following Mechanical Thrombectomy for Intermediate- and High-Risk Pulmonary Embolism: 6-Month FLASH Registry Results
Khandhar S, Jaber W, Bunte M, Cho K, Weinberg M, Mina B, Stegman B, Pollak J, Khosla A, Elmasri F, Zlotnick D, Brancheau D, Koenig G, Bisharat M, Li J, Toma C, Investigators F. Longer-Term Outcomes Following Mechanical Thrombectomy for Intermediate- and High-Risk Pulmonary Embolism: 6-Month FLASH Registry Results. Journal Of The Society For Cardiovascular Angiography & Interventions 2023, 2: 101000. PMID: 39131661, PMCID: PMC11307656, DOI: 10.1016/j.jscai.2023.101000.Peer-Reviewed Original ResearchChronic thromboembolic pulmonary hypertensionChronic thromboembolic diseaseRisk pulmonary embolismThromboembolic pulmonary hypertensionAcute pulmonary embolismPulmonary embolismFlowTriever SystemCause mortalityPulmonary hypertensionRV functionMechanical thrombectomyThromboembolic diseaseMedical Research Council dyspnea scoreHigh-risk pulmonary embolismTest distanceRapid hemodynamic improvementProportion of patientsRight ventricular functionSix-month outcomesQOL total scoreComers registryDyspnea scoreHemodynamic improvementMulticenter registryExercise capacity
2022
Neurovascular Dysregulation and Acute Exercise Intolerance in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome A Randomized, Placebo-Controlled Trial of Pyridostigmine
Joseph P, Pari R, Miller S, Warren A, Stovall MC, Squires J, Chang CJ, Xiao W, Waxman AB, Systrom DM. Neurovascular Dysregulation and Acute Exercise Intolerance in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome A Randomized, Placebo-Controlled Trial of Pyridostigmine. CHEST Journal 2022, 162: 1116-1126. PMID: 35526605, DOI: 10.1016/j.chest.2022.04.146.Peer-Reviewed Original ResearchConceptsME/CFSInvasive cardiopulmonary exercise testRight atrial pressureCardiac outputNeurovascular dysregulationAtrial pressurePostexertional malaiseExercise intoleranceMyalgic encephalomyelitis/chronic fatigue syndromePeak exercise oxygen uptakeRight ventricular filling pressuresEnd pointPlacebo-controlled trialPrimary end pointSecondary end pointsVentricular filling pressureCardiopulmonary exercise testChronic fatigue syndromeExercise oxygen uptakeA RandomizedIntractable fatigueOral pyridostigminePyridostigmine groupExercise capacitySystemic hemodynamicsImplementation of supervised exercise therapy in a veteran population with symptomatic claudication
Altin S, Schneider MD, Parise H, Banerjee S, Wu WC, Meadows JL, Pfau S, Keefe H, Armstrong EJ. Implementation of supervised exercise therapy in a veteran population with symptomatic claudication. Vascular Medicine 2022, 27: 136-141. PMID: 35225695, DOI: 10.1177/1358863x211073622.Peer-Reviewed Original ResearchConceptsExercise treadmill testingExercise therapyMetabolic equivalentsIntermittent claudicationExercise capacityTreadmill testingAnkle-brachial indexIntermittent claudication symptomsMale veteran patientsSupervised exercise therapySymptomatic intermittent claudicationVascular specialty clinicsLow patient adherenceClaudication symptomsSymptomatic claudicationExercise groupVeteran patientsPatient adherenceRisk stratificationTherapy referralSpecialty clinicProvider awarenessVeteran populationClaudicationTherapy
2021
Effect of Mavacamten on Echocardiographic Features in Symptomatic Patients With Obstructive Hypertrophic Cardiomyopathy
Hegde SM, Lester SJ, Solomon SD, Michels M, Elliott PM, Nagueh SF, Choudhury L, Zemanek D, Zwas DR, Jacoby D, Wang A, Ho CY, Li W, Sehnert AJ, Olivotto I, Abraham TP. Effect of Mavacamten on Echocardiographic Features in Symptomatic Patients With Obstructive Hypertrophic Cardiomyopathy. Journal Of The American College Of Cardiology 2021, 78: 2518-2532. PMID: 34915982, DOI: 10.1016/j.jacc.2021.09.1381.Peer-Reviewed Original ResearchConceptsObstructive hypertrophic cardiomyopathySystolic anterior motionAnterior motionDiastolic functionHypertrophic cardiomyopathyN-terminal pro-B-type natriuretic peptideMitral valve systolic anterior motionPro-B-type natriuretic peptidePeak exercise oxygen consumptionLeft ventricular diastolic functionVentricular outflow tract obstructionKey echocardiographic parametersAtrial volume indexOutflow tract obstructionVentricular diastolic functionExercise oxygen consumptionEffect of mavacamtenMyocardial wall stressEXPLORER-HCMLVOT gradientEchocardiographic featuresEchocardiographic parametersLVOT obstructionTract obstructionExercise capacityMineralocorticoid Receptor in Smooth Muscle Contributes to Pressure Overload–Induced Heart Failure
Kim S, Biwer L, Moss M, Man J, Aronovitz M, Martin G, Carrillo-Salinas F, Salvador A, Alcaide P, Jaffe I. Mineralocorticoid Receptor in Smooth Muscle Contributes to Pressure Overload–Induced Heart Failure. Circulation Heart Failure 2021, 14: e007279. PMID: 33517669, PMCID: PMC7887087, DOI: 10.1161/circheartfailure.120.007279.Peer-Reviewed Original ResearchConceptsSmooth muscle cellsMR-intact littermatesAdverse cardiac remodelingMineralocorticoid receptorCardiac remodelingSMC-MRAortic constrictionPressure overload-induced heart failureInhibition of MRRole of MRPressure overload-induced hypertrophyCardiac blood supplyHeart failure hospitalizationCardiac capillary densityCoronary flow reserveTransverse aortic constrictionIntracardiac pressure measurementsOverload-induced hypertrophyFibrotic gene expressionFetal gene expressionFailure hospitalizationExercise capacityExercise testingEjection fractionHeart failure
2020
Exercise capacity is associated with rest and peak-exercise left ventricular global longitudinal strain in patients with hypertrophic cardiomyopathy
Fava A, Alashi A, Saijo Y, Mathias I, Popovic Z, Thamilarasan M, Lever H, Desai M. Exercise capacity is associated with rest and peak-exercise left ventricular global longitudinal strain in patients with hypertrophic cardiomyopathy. European Heart Journal 2020, 41: ehaa946.0081. DOI: 10.1093/ehjci/ehaa946.0081.Peer-Reviewed Original ResearchLV-GLSHypertrophic cardiomyopathyExercise capacityHCM patientsVentricular global longitudinal strainGlobal myocardial strainSymptomatic HCM patientsReduced exercise capacitySubclinical cardiac dysfunctionSubclinical myocardial dysfunctionGlobal longitudinal strainLVOT gradientCardiac deteriorationExercise impairmentCardiac dysfunctionMyocardial dysfunctionMaximal exerciseExercise testExercise variablesClinical utilityFunctional capacityPatientsMyocardial strainLogistic regressionLongitudinal strainDiastolic stress test echocardiography in patients with hypertrophy cardiomyopathy: association with exercise capacity
Fava A, Mathias I, Alashi A, Saijo Y, Popovic Z, Thamilarasan M, Lever H, Desai M. Diastolic stress test echocardiography in patients with hypertrophy cardiomyopathy: association with exercise capacity. European Heart Journal 2020, 41: ehaa946.2087. DOI: 10.1093/ehjci/ehaa946.2087.Peer-Reviewed Original ResearchDiastolic dysfunctionExercise capacityLVOT gradientMaximal exerciseHCM patientsLate mitral inflow velocityLateral mitral annular velocityMitral E/eAbnormal diastolic responseSymptomatic HCM patientsAtrial volume indexReduced exercise capacityVentricular filling pressureMitral annular velocityMitral inflow velocityHypertrophic cardiomyopathy patientsLogistic regression analysisHypertrophy cardiomyopathyDiastolic responseMetabolic equivalentsCardiomyopathy patientsAnnular velocityFilling pressureFunctional capacityPatientsSystemic vascular distensibility relates to exercise capacity in connective tissue disease
Singh I, Oliveira RKF, Naeije R, Oldham WM, Faria-Urbina M, Waxman AB, Systrom DM. Systemic vascular distensibility relates to exercise capacity in connective tissue disease. Rheumatology 2020, 60: 1429-1434. PMID: 33001175, DOI: 10.1093/rheumatology/keaa510.Peer-Reviewed Original ResearchConceptsCTD patientsSystemic oxygen extractionExercise capacityVascular distensibilityCardiopulmonary diseaseOxygen extractionDecreased exercise capacityStroke volume augmentationReduced exercise capacityCommon clinical manifestationsRadial arterial catheterConnective tissue diseaseAerobic exercise capacityPulmonary vascular distensibilityCardio-pulmonary diseasePressure-flow plotsPulmonary hypertensionCardiopulmonary exerciseHeart failureArterial catheterExercise intoleranceTissue diseaseClinical manifestationsNormal controlsPatients
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply